Skip to main content
ADCT logo

ADCT · ADC Therapeutics SA

Track ADCT — free
$1.25 -0.05 (-3.78%)
Market Cap
$165.97M
Shares
127.67M
Volume · Nov 19 752.42K Avg daily vol (3M) 1.57M

Price & Indicators

 

Key stats

Close
$1.30
Open
$1.33
Day range
$1.29–1.41
52-week closing range
$0.96–4.88
Average volume, 30 days
1.4M
Short interest
6.4M · 5.0% of shares · 6.7 days
Short volume, last session
70%
Last earnings
Nov 9, 2026
Latest filing
10-Q · Nov 9
Price history
May 2020 to Nov 2026

Up next

Jan 11, 2027 Est · unconfirmed · in 7 wks
call held Jun 3, 2026

Latest documents

2026
Nov 10
Registration statement S-3
Registers resale of 61,000,000 shares after private placement

ADC Therapeutics SA registered up to 61,000,000 common shares for resale, covering 12,911,347 shares and 48,088,653 shares issuable from pre-funded warrants sold to institutional investors in the October 7, 2026 private placement.

Read from the first part of this long document
3 source passages
ADC THERAPEUTICS SA Pursuant to this prospectus, the selling shareholders may offer an aggregate of 61,000,000 common shares from time to time if and to the extent as they may determine as described in the section entitled “Plan of Distribution” at prevailing market prices, at prices different than prevailing market prices or at privately negotiated prices. As required by the securities purchase agreements, dated October 7, 2026, with the selling shareholders, we are filing the registration statement of which this prospectus forms a part to permit the resale of 12,911,347 common shares and 48,088,653 common shares issuable upon exercise of the pre-funded warrants, in each case, issued and sold to the selling shareholders pursuant to such securities purchase agreements. Open the document at this passage
Nov 9
Quarterly report 10-Q FY2026 Q3, ended Sep 30
LOTIS-5 significantly improved progression-free survival

ADC Therapeutics reported that Phase 3 LOTIS-5 showed significantly improved progression-free survival with ZYNLONTA plus rituximab versus R-GemOx in 420 patients; median PFS was 6.14 months versus 4.73 months.

Revenue $21.72M ▲ 32.2% Net loss $25.3M Diluted EPS -$0.16
Read from the MD&A section
3 source passages
ADC Therapeutics is a commercial-stage global pioneer in the field of antibody drug conjugates (“ADCs”), transforming treatment for patients through our focused portfolio with ZYNLONTA ® (loncastuximab tesirine-lpyl), a CD19-directed ADC. Full results from the randomized Phase 3 LOTIS-5 study of 420 patients demonstrated a statistically significant improvement in the primary endpoint of PFS with ZYNLONTA plus rituximab compared with R-GemOx. Median PFS by independent review was 6.14 months with ZYNLONTA plus rituximab versus 4.73 months with R-GemOx (HR 0.73; 95% CI, 0.57–0.92; P=0.0083). Open the document at this passage
Nov 9
Current report 8-K
Revenue rises as restructuring extends cash runway into 2029

ADC Therapeutics reported third-quarter net product revenue of $21.0 million and net loss of $25.3 million. Its October 2026 restructuring included an $86.6 million PIPE and extends expected cash runway into 2029.

Financial results
5 source passages
ADC Therapeutics Reports Third Quarter 2026 Financial Results and Provides Operational Updates Net product revenues were $21.0 million and $59.7 million for the third quarter and nine months ended September 30, 2026, as compared to $15.8 million and $51.2 million for the same periods in 2025. Net loss for the third quarter and nine months ended September 30, 2026, was $25.3 million or $74.8 million, or a net loss of $0.16 and $0.48 per basic and diluted share, as compared to a net loss of $41.0 million and $136.2 million, or a net loss of $0.30 and $1.14 per basic and diluted share, for the same periods in 2025. In October 2026, the Company announced a comprehensive strategic financial restructuring that included an $86.6 million private investment in public equity (PIPE) financing with participation from new investor Bain Capital Life Sciences and existing investors Redmile, TCGX, and Nantahala Capital. These transactions strengthened the Company's capital structure, enhanced strategic optionality and extended the expected cash runway into 2029. Open the document at this passage
Nov 4
Current report 8-K
ZYNLONTA trial results and cash runway into 2029

ADC Therapeutics reported ZYNLONTA trials with 88.7% ORR in LOTIS-7 and 93% in marginal zone lymphoma, plus preliminary cash of $189.2 million and an expected runway into 2029.

Financial results, Regulation FD disclosure, Other events
4 source passages
ADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), transforming treatment for patients through our focused portfolio with ZYNLONTA® (loncastuximab tesirine-lpyl). Phase 1b LOTIS-7 abstract data demonstrates an 88.7% ORR and 75.3% CR with ZYNLONTA plus glofitamab across the 97 efficacy-evaluable r/r DLBCL patients Phase 2 marginal zone lymphoma IIT abstract shows robust and durable 93% ORR and 74.4% CRR with ZYNLONTA monotherapy Expected cash runway into 2029 with cash and cash equivalents of $189.2 million as of September 30, 2026 and proforma cash post-refinancing of $196 million Open the document at this passage
Nov 3
Registration statement S-4
Delaware redomiciliation requires shareholder approval

ADC Therapeutics SA shareholders will vote on redomiciling from Switzerland to Delaware and adopting a certificate of incorporation and bylaws. The first two proposals lapse if redomiciliation is not completed by June 30, 2027.

Read from the first part of this long document
3 source passages
The board of directors of ADC Therapeutics SA, a Swiss stock corporation (*société anonyme*) organized under the laws of Switzerland (the “Company”), unanimously approved, and is submitting to our shareholders for approval at an extraordinary general meeting of shareholders (the “Meeting”) to be held at the date, time and location set forth above proposals that would change our jurisdiction of incorporation from Switzerland to the State of Delaware (the “Redomiciliation Transaction”). A proposal for a general amendment to the Company’s articles of association to replace such articles of association by the certificate of incorporation, the form of which is included in Annex B to this proxy statement/prospectus, and the bylaws, the form of which is included in Annex C to this proxy statement/prospectus, to be effective upon the Company becoming a corporation incorporated under the laws of the State of Delaware (the “Constitutive Documents Proposal”). If the Company does not become a corporation incorporated under the laws of the State of Delaware by June 30, 2027, any approval of the first and second proposals described above will lapse. Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$84.87M
Trailing 12 months
Net income (TTM)
−$81.25M
Trailing 12 months
Revenue growth YoY
+32.2%
Year over year
Operating margin
-97.7%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-60.6%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+13.9%
Year over year · more shares
Price change (1Y)
-67.7%
Trailing year
Short interest
5.0%
Latest settlement · 6.7 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Very Weak Sentiment Bearish Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 28.4 · fear Equity put/call 0.72
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −44%
below
Price vs 50-day avg −7%
below
RSI (14) 43
neutral
MACD trend Negative
52-week position 9%
near low
Volume (OBV) Bullish div.
accumulating
Momentum
relative strength
Very Weak
1-month return −19%
trailing
6-month return −62%
trailing
YTD return −63%
this year
Relative strength −56%
vs S&P · 6-mo
Sentiment
smart money
Bearish
Trend (MA cross) No cross
50d $1 › 200d $2 — 200d above 50d
Institutional flow Distributing
-3% holders QoQ · +18 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
5.03% of shares out · ▲ +1.4% MoM · 6.7 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
110 holders — mid 3-yr range
Squeeze score 66
elevated · 0–100
Fundamentals
Strong
Revenue growth +15%
Y/Y
EPS growth +31%
Y/Y
Free cash flow $-141.4M
Quant / Vol
risk profile
Very High
Volatility 100%
annualized · 1-yr
Max drawdown −80%
past year
ATR 12.3%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the Earnings Call filed Jun 3, 2026
Peak annual revenues of ZYNLONTA in the U.S. · peak annual $600M – $1B
Previous outlook earlier release · from the Earnings Call filed Mar 10, 2026

Still-open targets the latest release did not restate under the same label.

Total peak revenue opportunity for ZYNLONTA · peak $600M – $1B
Prior guidance period ended · from the 8-K filed Nov 4, 2026
Net product revenues from sales of ZYNLONTA · third quarter ended September 30, 2026 $21M

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Sell
4 · 2 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−44% Bearish
Price vs 50-day avg
−7% Bearish
RSI (14)
43 Neutral
MACD trend
Negative Bearish
52-week position
9% Bearish
Volume (OBV)
Bullish div. Bullish
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50d $1 › 200d $2 — 200d above 50d
Institutional flow Distributing
-3% holders QoQ · +18 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
5.03% of shares out · ▲ +1.4% MoM · 6.7 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
110 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1 Now $1 · 9% Range high $5
vs 200-day avg -44% vs 50-day avg -7%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Adjusted net loss non-GAAP $36M six months ended June 30, 2026 —
Adjusted net loss per share, basic and diluted non-GAAP $0.23 Six Months Ended June 30, 2026 —
Adjusted total operating expenses non-GAAP $80.1M six months ended June 30, 2026 —
annualized estimated cost savings $10M second quarter 2026 —
workforce reduction 17% second quarter 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Drug Manufacturers - Specialty & Generic — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
ADCT
ADC Therapeutics SA
this stock
$165.97M -63.2% +14.9% — 5.0%
TAK
Takeda Pharmaceutical Co Ltd
$68.40B +37.3% — — 0.1%
GALDY
Galderma Group AG
$50.89B +5.3% — — 0.0%
TEVA
Teva Pharmaceutical Industries Ltd
$44.97B +23.5% +4.3% 87.6 2.4%
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
$40.66B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
110
% held
64.2%
Net QoQ
+1.2M sh
Top holder
Nantahala Capital Managem…
Held Float
View
Held by Funds
Fund positions
22
View
Short & Settlement
Short Interest Rising
Shares short
6.4M
Days to cover
6.7d
Change
+88.0K sh
View
Short Volume
Short vol %
70%
As of
Nov 19, 2026
Short Total
View
Fails to Deliver
FTD shares
524
Value
$744
As of
Oct 8, 2026
View
Off-Exchange
Off-exchange %
42.1%
Week of
Oct 12, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$81.4M
Net income (FY)
$-142.6M
EPS diluted
$-1.12
View
Filings
SEC Filings
Latest
S-3
Filed
Nov 10, 2026
This year
24

ADC Therapeutics SA registered up to 61,000,000 common shares for resale, covering 12,911,347 shares and 48,088,653 shares issuable from pre-funded warrants sold to institutional investors in the October 7, 2026 private placement.

View
Proposed Sales
Value
$20.2K
Shares
7.0K
Filed
Jun 18, 2024
View
Earnings & Events
Webcasts
Last webcast
Nov 19, 2026
View
Investor Relations
Latest news
ADC Therapeutics Reports Third Qu…
Published
Nov 9, 2026
View

Performance

5D 20D 120D MTD YTD
ADCT -7.8% -18.8% -61.8% -15.0% -63.2%
SPY -5.5% -6.3% -5.6% -5.3% +5.0%
vs SPY -2.4% -12.5% -56.1% -9.8% -68.2%
Key facts CIK 1771910 CUSIP H0036K147 13F (30d) 116 filings 102 filers Visit website Investor relations